MAINZ, GERMANY--(Marketwire - August 04, 2010) -
GANYMED Pharmaceuticals AG / Clinical Phase I Results of GANYMED's iMAB362
Antibody Demonstrate Excellent Safety processed and transmitted by Hugin
AS. The issuer is solely responsible for the content of this announcement.
A clinical first-in-human Phase I multi center
study with GANYMED's monoclonal antibody iMAB362 demonstrated excellent
up to a dosis of 1g/sqm in gastro-esophageal cancer patients. iMAB362
GANYMED's proprietary cell surface antigen Claudine 18.2, which is present
70% of all gastric cancers, 50% pancreatic cancers, 30% esophageal cancers
25% non small cell lung (NSCL) cancers. In preclinical cancer models
demonstrated potent antitumor activity against Claudine 18.2 positive
GANYMED's uniquely cancer specific targets are expressed in the majority of
solid cancers and are crucial for cancer growth, proliferation and
Company controls a broad and robust pipeline of highly effective cancer
antibodies. With iMAB362 spearheading GANYMED's cancer antibody pipeline,
Company is uniquely positioned to penetrate a large portion of the solid
market in major indications with strong unmet medical need, including
gastro-esophageal, pancreatic, breast, colon, NCSL, ovarian and prostate
The very positive outcome of GANYMED's first-in-human study with iMAB362
GANYMED's the transformation into a strong development organization with a
proprietary anti cancer target and antibody pipeline of significant value.
"The proven safety and tolerability even at high drug levels confirms
concept based on highly cancer specific targets for developing potent
with an excellent safety profile. The Company's anti cancer antibodies are
exquisitely positioned to meet current and future needs in solid cancer
therapeutics to substantially improve patient care," said Prof. Rolf Krebs,
Chairman of the Supervisory Board of GANYMED. "As for iMAB362, this very
successful Phase I study paves the way for several Phase II studies in
gastro-esophageal and pancreatic cancer."
About GANYMED Pharmaceuticals AG
GANYMED Pharmaceuticals AG is a leading biopharmaceutical company offering
antibody therapeutics for ideal targets (iMAB) in solid cancers. GANYMED's
unique expertise in pinpointing truly cancer specific proprietary targets
basis for the company's growing sustainable pipeline of antibody
with unique tumor specificity targeting solid cancers with high unmet
need. Because GANYMED's proprietary cell surface cancer targets have
tumor cell specificity, iMABs can efficiently kill tumor cells without
normal tissues. Therefore, the Company's iMABs can unleash the full
of therapeutic antibodies via separate but synergistic biological attacks
focused solely on the cancer cells: (i) direct suppression of tumor growth,
antibody dependent cellular cytotoxicity (ADCC), (iii) antibody dependent
complement lysis (CDC), and (iv) induction of apoptosis.
In addition to its lead antibody, iMAB362, which will commence Phase II
in gastro-esophageal and pancreatic cancer shortly, GANYMED has several
antibody projects against solid cancers in development, including ovarian,
breast, colorectal, NCSL and prostate cancers.
GANYMED is a private German biopharmaceutical company supported by highly
successful investors with a wealth of experience in backing successful life
science entrepreneurs. GANYMED's majority shareholder is ATS
Beteiligungsverwaltung GmbH. Other investors include: Future Capital AG,
and private individuals.
GANYMED Pharmaceuticals AG
Rainer Wessel, PhD
CBO & Spokesman
t: +49 (0) 61 31 14 40 100
--- End of Message ---
GANYMED Pharmaceuticals AG
Freiligrathstraße 12 Mainz Germany
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: GANYMED Pharmaceuticals AG via Thomson Reuters ONE